Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Inflammatory Choroidal Neovascularization (CNV) in Young Patients.

NCT02556229 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.

NCT NCT02556229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02556229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Inflammatory Choroidal Neovascularization (CNV) in Young Patients.
Lead sponsor
Hospices Civils de Lyon
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2016
Completion date
September 30, 2019
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

inflammatory choroidal neovascularization